Taxane resistance in prostate cancer is mediated by decreased drug-target engagement

Despite widespread use of taxanes, mechanisms of action and resistance in vivo remain to be established, and there is no way of predicting who will respond to therapy. This study examined prostate cancer (PCa) xenografts and patient samples to identify in vivo mechanisms of taxane action and resista...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Invest
Auteurs principaux: Gjyrezi, Ada, Xie, Fang, Voznesensky, Olga, Khanna, Prateek, Calagua, Carla, Bai, Yang, Kung, Justin, Wu, Jim, Corey, Eva, Montgomery, Bruce, Mace, Sandrine, Gianolio, Diego A., Bubley, Glenn J., Balk, Steven P., Giannakakou, Paraskevi, Bhatt, Rupal S.
Format: Artigo
Langue:Inglês
Publié: American Society for Clinical Investigation 2020
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7259995/
https://ncbi.nlm.nih.gov/pubmed/32478682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI132184
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires